Targeted Cancer Sequencing

Targeted Sequencing to Identify Known Mutations

Targeted cancer sequencing focuses on a select set of genes, gene regions, or amplicons that are selected based on a priori knowledge. By sequencing only known cancer-relevant genes, researchers can perform sequencing more cost-effectively, with a more streamlined data analysis pipeline.

With our complete workflow for building biomarker profiles of tumors, you’ll access high-quality information, even from limited and challenging sample material, such as FFPE.

Targeted Cancer Sequencing Solutions

Fixed Content Panels

To facilitate targeted cancer next-generation sequencing (NGS) studies, Illumina offers fixed content sets for guaranteed performance and a custom amplicon solution where researchers can choose their amplicons of interest. The table below lists key features of each targeted cancer sequencing panel.

Table: Cancer PanelsView Cancer Panels »

 

 

Cancer Panel Comparison Table

Cancer Panel Comparison Tool

Find the cancer panel that best fits your needs with this easy comparison table.
View Table (PDF) »

 

Custom Targeted Sequencing

For researchers who would prefer to customize their targeted sequencing studies, TruSeq Custom Amplicon (TSCA) enables rapid and efficient sequencing of hundreds of genomic regions covering up to 650 kb of cumulative sequence. It is amenable to a wide range of sample types, including FFPE samples.

This fully integrated DNA-to-data solution includes probe design and ordering using DesignStudio, an easy-to-use online software tool that provides dynamic feedback to optimize design and region coverage.

Illumina also offers custom enrichment kits to target 0.5-25 Mb of custom content. The Nextera Custom Enrichment Kit combines the fastest workflow and customized probe design for an integrated, end-to-end custom targeted cancer exome sequencing solution.

Amplicon-Based Tumor Profiling

Creating high-quality molecular profiles of tumors from precious and challenging samples has never been easier. Now, with our seamless tumor profiling workflow, you can get the answers you seek faster and more efficiently by sequencing multiple genes of interest in a single run and eliminating the need for iterative gene testing.

Illumina workflow solutions are making NGS more accessible and empowering than ever before.

  • Training from library prep through data analysis for fast and easy start-up
  • One-stop access to expert, technical support across the complete workflow
  • Seamless data streaming from sequencers into the BaseSpace Platform
  • Push-button data analysis on the BaseSpace Platform

Illumina NGS and Cancer

How Next-Generation Sequencing is Revolutionizing Cancer DiagnosesIllumina Next-Gen Sequencing: Think Big, Start Small

Kenneth Bloom, MD, FCAP, Chief Medical Officer at Clarient (GE Healthcare), discusses the practical aspects of how NGS will be applied in clinical labs.

Targeting Cancer Genes

TruSight Myeloid Sequencing Panel

TruSight Myeloid Panel
The assay includes 15 full genes (exons only) and 39 additional genes where oncogenic hotspots are covered.
View Assay »

 

MiSeq
Run TruSight Myeloid Panel on the MiSeq system, then use MiSeq Reporter for analysis and variant calling.
View System »

Get help in choosing the right cancer research solution for you. Contact us »